.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, using up the best science place at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma’s main clinical police officer and also international head of research, Sanofi told Tough Biotech in an emailed claim.Quigley is switching out Frank Nestle, M.D., that left Sanofi this spring season among an international overhaul of the provider’s R&D device. Nestle, who invested eight years with the pharma, jumped over to Deerfield Monitoring, where he currently works as a partner on the therapeutics team as well as chief executive officer of the agency’s therapeutic exploration and progression operations.
Quigley will join Sanofi coming from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile. He is actually currently listed as the firm’s co-founder, head of state and chief executive officer.Because August 2021, Quigley has functioned as a venture companion at SV Wellness Investors, a health care fund manager with existing investments in biotechs including BioAge, Cerevance, Dualitas Therapies as well as Nimbus Rehabs, to name a few. Quigley formerly kept the top area at Dualitas, a biotech that remains in stealth, according to STAT.The soon-to-be Sanofi forerunner additionally formerly helmed Therini Biography, an immunotherapy biotech working to create therapies for neurodegenerative health conditions driven by vascular dysfunction.Just before devoting the last few years in biotech, Quigley possesses an also longer track record in Big Pharma, most lately acting as Gilead’s senior bad habit president of research biology up until the summer season of 2021.
Just before that, he appeared much more than 4 years across different leadership duties at Bristol Myers Squibb and also worked as a medical director at Johnson & Johnson’s Janssen upper arm prior to that.Sanofi mentioned Quigley’s purpose in his new role would be to “optimize our probability of results by means of ideal partnerships around our institution and also past, bringing best-in-class technology in addition to developing and also sourcing new industry-leading talent along with a dedication to variety,” according to an inner memorandum obtained through STAT.